Drug Profile


Alternative Names: ACT-129968; KYTH-105

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Actelion Pharmaceuticals
  • Developer Actelion Pharmaceuticals; Kythera Biopharmaceuticals
  • Class Antiasthmatics; Small molecules
  • Mechanism of Action Prostaglandin D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alopecia
  • Discontinued Asthma; Seasonal allergic rhinitis

Most Recent Events

  • 01 Jun 2016 Phase-II clinical trials in Alopecia in USA (PO) (NCT02781311)
  • 01 Oct 2015 Kythera Biopharmaceuticals has been acquired by Allergan
  • 22 Sep 2015 KYTHERA Biopharmaceuticals files an IND application with the FDA in USA for Alopecia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top